A Photodynamic Therapy for Treatment of Actinic Keratoses
NCT ID: NCT00558688
Last Updated: 2021-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2007-08-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Light Therapy
Photodynamic therapy
Photodynamic therapy applied to actinic keratoses
2
Light Therapy
Photodynamic therapy
Photodynamic therapy applied to actinic keratoses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Photodynamic therapy
Photodynamic therapy applied to actinic keratoses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a t least 4 nonhypertrophic AK lesions on the body
* The subjects are in good health
* The subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate to the investigator
Exclusion Criteria
* Subjects with a history of cutaneous photosensitivity or porphyria, hypersensitivity to porphyrins, or photodermatosis
* Subjects with use of photosensitizing drugs within 1 week of study start
* Subjects with use of topical medications such as corticosteroids, alpha-hydroxyacids or retinoids 2 weeks before study entry
* Subjects with systemic steroid therapy within 4 weeks before study entry
* Subjects who received previous treatment of target AKs
* Subjects with systemic treatment with chemotherapeutic agents, masoprocol (Actinex), immunotherapy, or retinoids within 2 months of study entry
* Subjects with prior history of hypersensitivity reactions to lidocaine
* Subjects who are unable to understand the protocol or to give informed consent
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northwestern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Murad Alam
Professor in Dermatology, Otolaryngology-Head and Neck Surgery, and Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Murad Alam, MD
Role: PRINCIPAL_INVESTIGATOR
Northwestern University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwestern University Department of Dermatology
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STU00000312
Identifier Type: -
Identifier Source: org_study_id